Garbo Garrett, Barrera Ellis, Shim Jessica Y, Boskey Elizabeth R, Grimstad Frances W
Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, Minnesota; Division of Gynecology, Department of Surgery, Boston Children's Hospital, Boston, Massachusetts; Frank H Netter School of Medicine at Quinnipiac University, North Haven, Connecticut.
Division of Gynecology, Department of Surgery, Boston Children's Hospital, Boston, Massachusetts.
J Adolesc Health. 2025 Jan;76(1):148-153. doi: 10.1016/j.jadohealth.2024.09.004. Epub 2024 Oct 10.
To describe experiences of adolescents taking continuous drospirenone (DRSP-C) oral contraceptives, without placebo, for menstrual suppression, including breakthrough bleeding and other side-effects.
This was a retrospective chart review of adolescents prescribed DRSP-C for menstrual suppression. Demographics and indications for DRSP-C were collected on the visit where DRSP-C was prescribed. Data through the final follow-up visit during the study period included documented effects and side-effects of DRSP-C and continuation of therapy. Statistical analyses were primarily descriptive.
Patients prescribed DRSP-C were included (n = 136). Dysmenorrhea was the most common indication for DRSP-C (58.8%, n = 80/136) followed by endometriosis (44.8%, n = 61/136). The median time on DRSP-C for the 116 patients who were able to initiate treatment was 12.3 months (interquartile range [IQR] 6.8, 17.4). Patients trialed, on average, 2 other forms of menstrual management before starting DRSP-C (IQR 1, 3). Pelvic pain or dysmenorrhea resolution or improvement was reported in 84.6% (44/52) of dysmenorrhea patients, and 77.8% (28/36) of pelvic pain patients. Almost half of patients reported breakthrough bleeding on DRSP-C (41.3%, n = 48/116); however, only 11 patients (42%, 11/26) discontinued DRSP-C because of it. Within the study period, 22.4% (n = 26/116) of patients discontinued DRSP-C, with a median treatment duration of 101 days (IQR 71, 157). Among patients who discontinued DRSP-C, the most common reason was breakthrough bleeding (42%, n = 11/26).
DRSP-C for menstrual suppression was well tolerated in adolescents, with most patients reporting resolution or improvement of their indication for taking DRSP-C. Findings demonstrate DRSP-C is a viable option for menstrual suppression in adolescents.
描述青少年服用不含安慰剂的连续服用屈螺酮（DRSP-C）口服避孕药进行月经抑制的经历，包括突破性出血和其他副作用。
这是一项对开了DRSP-C用于月经抑制的青少年进行的回顾性病历审查。在开DRSP-C的就诊时收集了人口统计学资料和使用DRSP-C的指征。研究期间直至最后一次随访的数据包括记录的DRSP-C的效果和副作用以及治疗的持续情况。统计分析主要是描述性的。
纳入了开了DRSP-C的患者（n = 136）。痛经是使用DRSP-C最常见的指征（58.8%，n = 80/136），其次是子宫内膜异位症（44.8%，n = 61/136）。116名能够开始治疗的患者使用DRSP-C的中位时间为12.3个月（四分位间距[IQR] 6.8，17.4）。患者在开始使用DRSP-C之前平均尝试过2种其他月经管理方式（IQR 1，3）。84.6%（44/52）的痛经患者和77.8%（28/36）的盆腔疼痛患者报告盆腔疼痛或痛经缓解或改善。几乎一半的患者报告在服用DRSP-C期间出现突破性出血（41.3%，n = 48/116）；然而，只有11名患者（42%，11/26）因此停用DRSP-C。在研究期间，22.4%（n =
